LipiFlow Treatment for Meibomian Gland Dysfunction Approved by FDA

July 12, 2011

Submit Comments
Dr. Ari Weitzner

TearScience, Inc., announced yesterday that the FDA had cleared its LipiFlow® Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), one of the leading causes of dry eye. The clearance enables TearScience to market and sell LipiFlow® to eye care physicians in the U.S. LipiFlow® will be available immediately, but on a limited basis in the U.S. through the end of 2011. LipiFlow® removes meibomian gland obstructions by applying directed energy to a patient’s eyelid during a 12-minute in-office treatment.

Click here to learn more.

 

 

Comments (2) Trackbacks Print this post
 

Bookmark

 
Filed in Dry Eye, Industry News, New Technologies Tagged , ,
You might also enjoy...

Comments

Jump down to form below to submit your own comments

2 Responses to “LipiFlow Treatment for Meibomian Gland Dysfunction Approved by FDA”

  1. Harold Pechakjian on September 26th, 2011 10:04 pm

    Are there any Doctors in the southern california area who are performing Lipiflow?

    Thanks.

  2. ari on September 26th, 2011 11:25 pm

    i dont know- sorry

Trackback URL
http://eyedocnews.com/005695-lipiflow-treatment-for-meibomian-gland-dysfunction-approved-by-fda/trackback/

Have insights to contribute? Please submit your comment below